Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Ideaya Biosciences shares receives Buy rating, $55 price target from BTIG

EditorNatashya Angelica
Published 03/08/2024, 05:58 AM
© Reuters.
IDYA
-

On Thursday, Ideaya Biosciences (NASDAQ:IDYA), a clinical-stage biotechnology company, received a new Buy rating from BTIG, with a stock price target set at $55.00. The coverage initiation reflects a positive outlook on the company's potential in the oncology sector, particularly with its lead drug, darovasertib, and its pipeline of first-in-class molecules.

BTIG highlighted Ideaya Biosciences' strong financial position, which is seen as providing multiple opportunities for value creation for investors. The firm's lead drug, darovasertib, is noted for showing promising clinical data in treating patients with HLA-A2(-) uveal melanoma, a condition currently not addressed by Immunocore's KIMMTRAK.

The analyst firm is also optimistic about Ideaya Biosciences' MAT2A inhibitor program, IDE397, which targets MTAP-deleted tumors with a unique approach. BTIG is closely monitoring the progress of the company's PRMT5 inhibitor combination program, suggesting it has the potential to become best-in-class.

According to BTIG, the early-stage pipeline at Ideaya Biosciences, which includes IDE161 and Werner helicase programs, is currently underappreciated by the market. The firm anticipates that additional proof-of-concept data for these programs could further unlock value for the company.

Ideaya Biosciences' new rating and price target reflect the firm's confidence in the company's strategic approach to developing treatments for various oncologic indications. The company's focus on novel molecular pathways and combination therapies is expected to position it well within the competitive landscape of oncology treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.